Post-transplant Management in Heart Transplant Recipients: New Drugs and Prophylactic Strategies

Keyphrases

• Heart Transplant 100%
• Heart Transplant Recipients 100%
• New Drugs 100%
• Drug Strategy 100%
• Post-transplant Management 100%
• Prophylactic Strategy 100%
• Pathologic 50%
• Cancer Immunotherapy 50%
• Heart Transplantation 50%
• Plasma Cells 50%
• Malignancy 50%
• Median Survival 50%
• Transplantation 50%
• Autoimmune Disease 50%
• Gene Expression Profiling 50%
• B Cells 50%
• End-stage Heart Failure 50%
• Immunosuppression 50%
• 1-year Survival 50%
• Long-term Complications 50%
• Mechanical Circulatory Support 50%
• Older Donors 50%
• Donor Age 50%
• Antibody-mediated Rejection 50%
• Rejection Surveillance 50%
• Critically Ill 50%
• Waitlist Mortality 50%
• Systems Change 50%
• Cell Cytokines 50%
• Coronary Allograft Vasculopathy 50%
• Recent Innovation 50%
• Allosensitization 50%
• Donation after Circulatory Death 50%
• Novel Immunosuppression 50%
• Support Use 50%
• Hepatitis C Donor 50%
• Heart Allocation Policy 50%
• Pathway Targeting 50%
• Contemporary Landscapes 50%

Immunology and Microbiology

• Immunosuppression 100%
• Cytokine 50%
• Immunoglobulin Producing Cell 50%
• B Cell 50%
• Gene Expression Assay 50%
• Autoimmune Disease 50%
• Heart Transplantation 50%
• Hepatitis C 50%
• Antibody Mediated Rejection 50%
• Allograft Vasculopathy 50%
• Cancer Immunotherapy 50%
• Infection 50%

Medicine and Dentistry

• Heart Graft 100%
• Immunosuppressive Treatment 66%
• Cancer 33%
• Infection 33%
• Congestive Heart Failure 33%
• Cancer Immunotherapy 33%
• Heart Transplantation 33%
• Immunoglobulin Producing Cell 33%
• Cytokine 33%
• Autoimmune Disease 33%
• Gene Expression Profiling 33%
• B Cell 33%
• Hepatitis C 33%
• Assisted Circulation 33%
• Antibody Mediated Rejection 33%
• Cardiac Allograft Vasculopathy 33%